Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer’s Disease
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
2426-0266
- Extent
-
Online-Ressource
- Language
-
Englisch
- Notes
-
online resource.
- Bibliographic citation
-
Clinical Trial Endpoints and Their Clinical Meaningfulness in Early Stages of Alzheimer’s Disease ; day:26 ; month:4 ; year:2022 ; pages:1-16
The journal of prevention of Alzheimer's disease ; (26.4.2022), 1-16
- Creator
-
Cohen, Sharon
Cummings, J.
Knox, S.
Potashman, M.
Harrison, J.
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.14283/jpad.2022.41
- URN
-
urn:nbn:de:101:1-2022070909251785060316
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:27 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Cohen, Sharon
- Cummings, J.
- Knox, S.
- Potashman, M.
- Harrison, J.
- SpringerLink (Online service)
Other Objects (12)
Imaging endpoints for clinical trials in Alzheimer’s disease
A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer’s Disease
Predicting early Alzheimer’s with blood biomarkers and clinical features
Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021
Automated detection of early-stage Alzheimer’s Disease
A randomized clinical trial evaluating Hydralazine’s efficacy in early-stage Alzheimer’s disease: The EHSAN Study
Alzheimer’s Disease: Epidemiology and Clinical Progression
Author Correction: Predicting early Alzheimer’s with blood biomarkers and clinical features
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review
Can cognitive assessment really discriminate early stages of Alzheimer’s and behavioural variant frontotemporal dementia at initial clinical presentation?
Drug candidates in clinical trials for Alzheimer’s disease
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
Imaging endpoints for clinical trials in Alzheimer’s disease
A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer’s Disease
Predicting early Alzheimer’s with blood biomarkers and clinical features
Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021
Automated detection of early-stage Alzheimer’s Disease
A randomized clinical trial evaluating Hydralazine’s efficacy in early-stage Alzheimer’s disease: The EHSAN Study
Alzheimer’s Disease: Epidemiology and Clinical Progression
Author Correction: Predicting early Alzheimer’s with blood biomarkers and clinical features
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review
Can cognitive assessment really discriminate early stages of Alzheimer’s and behavioural variant frontotemporal dementia at initial clinical presentation?
Drug candidates in clinical trials for Alzheimer’s disease
BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease
Imaging endpoints for clinical trials in Alzheimer’s disease
A Statistical Framework for Assessing the Relationship between Biomarkers and Clinical Endpoints in Alzheimer’s Disease
Predicting early Alzheimer’s with blood biomarkers and clinical features
Diagnosis of Early Alzheimer’s Disease: Clinical Practice in 2021
Automated detection of early-stage Alzheimer’s Disease
A randomized clinical trial evaluating Hydralazine’s efficacy in early-stage Alzheimer’s disease: The EHSAN Study
Alzheimer’s Disease: Epidemiology and Clinical Progression
Author Correction: Predicting early Alzheimer’s with blood biomarkers and clinical features
Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer’s disease: a systematic review
Can cognitive assessment really discriminate early stages of Alzheimer’s and behavioural variant frontotemporal dementia at initial clinical presentation?
Drug candidates in clinical trials for Alzheimer’s disease